A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
about
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsAdvances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersHsp90 as a Potential Therapeutic Target in Retinal DiseaseHeat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an updateTargeting heat shock protein 90 for the treatment of malignant pheochromocytomaHeat shock protein 90 inhibition: rationale and clinical potential.Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity.Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsA first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabineCombination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.Targeted therapies for lung cancer: clinical experience and novel agentsDelivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemiaHSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma.Cancer stem cells, microRNAs, and therapeutic strategies including natural products.Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignanciesTargeting heat shock proteins in metastatic castration-resistant prostate cancer.Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerTargeting cancer cell mitochondria as a therapeutic approach: recent updates.The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.Delivery of HSP90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload.Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS).
P2860
Q26740374-A403E906-33F4-4CE3-9FDB-8632864F6567Q27022514-E19E7E3B-B45E-4FE4-8707-26451371E228Q28083847-F0E125B7-79A7-4508-88F2-75AB96509152Q28272905-3F33A4FC-5187-4033-9E5A-624D0497FC5FQ28486170-0660DD67-FF47-4B5A-B4E7-0C73782C8066Q30418761-DF4B8EB3-CF9A-49EB-99FE-85FA1D7F01BBQ33163062-80470F71-127C-4A26-993E-6A8C8A30200CQ33584583-FA9E725E-C4D1-4DAD-A9BC-1F4D5CBB40D2Q34085148-140F3ABC-2428-4FA4-9E24-60C34822605EQ34164027-126EC03E-037F-4A25-BE26-9C85C619D471Q34636437-74A7B803-471C-4802-A410-57F156A2C5C2Q35054403-DA8ABC70-52F4-458A-A0DB-872046F9239CQ35673943-661DF890-883D-409F-AED3-A341D9597B2EQ35859205-12F369E6-2DA0-4D07-AB07-11A63F7BE646Q36054970-E1CBFA16-ADA1-48BC-8F7C-3DD7C67F9098Q36257738-A2CB84D1-A225-4AFB-9E13-18AFB4BEE32FQ36465517-D693DF62-4E41-4A11-AACE-D14CE40BEA44Q36472987-138B6C67-5A6D-4535-9BD9-4724A9EFF404Q36562242-928B1CD9-F2AE-4EB6-88A0-0EB6875C9A27Q37060950-D0079F8C-54F9-41CB-A5B9-190D94DCA320Q38023238-41A7A270-65F0-448D-8500-FBD2889983B3Q38166527-F1C0050B-796A-4389-96DC-43B7E06B53F1Q38289945-99615E42-1DFE-4286-A7A6-9AD48E9493C0Q38382840-67572D48-DE67-4067-B12C-6DB001BD59CCQ38648408-DAC6FAF8-3272-46FF-97B8-DEBD8B02B602Q38668524-6167A1A8-ED3A-478E-B7D0-FE1A1C292845Q38848546-E2F0ACA9-A0FD-4217-A78E-DC4CB9B18AD6Q38988815-553C78B9-BC80-4458-B1BB-F44D9A134A20Q42362272-1ECBA984-ADE0-4FD1-BFFB-08A5918CEC36Q47797544-3E8889A1-5818-4D76-B354-BB3ADA62557BQ54660067-3C1F29FA-525A-4F35-A96B-25867F7533E5
P2860
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase I study of PF-04929113 ...... or malignancies and lymphomas.
@ast
A phase I study of PF-04929113 ...... or malignancies and lymphomas.
@en
type
label
A phase I study of PF-04929113 ...... or malignancies and lymphomas.
@ast
A phase I study of PF-04929113 ...... or malignancies and lymphomas.
@en
prefLabel
A phase I study of PF-04929113 ...... or malignancies and lymphomas.
@ast
A phase I study of PF-04929113 ...... or malignancies and lymphomas.
@en
P2093
P2860
P1476
A phase I study of PF-04929113 ...... or malignancies and lymphomas.
@en
P2093
Arun Rajan
Brett E Houk
Jane B Trepel
Lokesh Jain
Martin Gutierrez
Michael Shnaidman
Nicoletta Brega
Ronan J Kelly
Shivaani Kummar
Sonja Crandon
P2860
P304
P356
10.1158/1078-0432.CCR-11-0821
P407
P577
2011-09-09T00:00:00Z